PT 141 is a peptide sold as bremelanotide for low sexual desire. Learn what it does, how it works, dosing facts, side effects, and research status.
PT-141 is the development code for bremelanotide, a synthetic peptide that activates melanocortin receptors in the brain to influence sexual desire. It is the active ingredient in Vyleesi, an FDA-approved prescription autoinjector for premenopausal women with hypoactive sexual desire disorder (HSDD). PT-141 is not a blood-flow drug like Viagra, because it works on the central nervous system rather than on blood vessels.
What Is PT-141? The Short Answer
PT-141 is a cyclic heptapeptide, which means it is built from seven amino acids arranged in a ring. Chemically, it is an analog of alpha-melanocyte-stimulating hormone (alpha-MSH), a peptide the human body already produces.
People searching what is pt-141 are usually looking for the naming. PT-141 is the research code, bremelanotide is the generic name, and Vyleesi is the brand name. A frequent point of confusion is is bremelanotide the same as pt 141 — it is, and all three names describe the same molecule.
The compound started out in a completely different category. It came from the same research family as melanotan II, an unapproved tanning peptide, and early studies focused on skin pigmentation. Researchers noticed changes in sexual desire as a side effect, and that observation redirected the drug's development.
PT-141 Mechanism of Action
PT-141 binds to melanocortin receptors, with its strongest activity at the MC4 receptor (MC4R). MC4R is heavily concentrated in the hypothalamus, a brain region that helps regulate appetite, arousal, and motivation.
By activating those receptors, PT-141 appears to influence central pathways tied to sexual motivation rather than mechanical arousal. In plain terms, it acts more on desire than on blood flow, which is why it is often described as a desire treatment instead of a performance one.
That mechanism is the main difference between PT-141 and PDE5 inhibitors such as sildenafil. PDE5 inhibitors relax smooth muscle and increase blood flow to the genitals, while PT-141 works upstream in the brain.
| Feature | PT-141 (bremelanotide) | Sildenafil (Viagra) | Flibanserin (Addyi) |
|---|---|---|---|
| Primary target | Melanocortin receptors, mainly MC4R, in the brain | PDE5 enzyme in vascular tissue | Serotonin receptors in the brain |
| Route | Subcutaneous injection | Oral tablet | Oral tablet |
| Timing before activity | About 45 minutes | About 30 to 60 minutes | Daily, at bedtime |
| FDA-approved for | HSDD in premenopausal women | Erectile dysfunction in men | HSDD in premenopausal women |
| Most common side effect | Nausea | Headache and flushing | Sleepiness and dizziness |
How PT-141 Is Dosed and How Long It Lasts
The approved regimen is 1.75 mg injected under the skin of the abdomen or thigh, at least 45 minutes before anticipated sexual activity. The label limits use to one dose in 24 hours and no more than eight doses per month.
One of the most common questions is pt-141 how long does it take to work, and most users report noticing effects within roughly 30 to 60 minutes of the injection. The related question pt-141 peptide how long does it last is less precise, because reported effects generally run for a few hours while some people describe lingering benefit into the next day.
An older nasal spray version was studied at higher doses but was never approved. That nasal program was discontinued after reports of blood pressure increases, which is part of why the injectable form is the only version available by prescription in the United States.
| Item | Typical detail |
|---|---|
| Form | Subcutaneous autoinjector, 1.75 mg |
| Onset | About 30 to 60 minutes |
| Reported duration | A few hours, sometimes longer |
| Maximum frequency | 1 dose per 24 hours, up to 8 doses per month |
| Prescription status in the US | Prescription only, not approved for men |
Side Effects, Safety, and Legal Status
Nausea is the most frequently reported side effect, affecting roughly 40% of participants in clinical trials. Flushing, headache, injection site reactions, and short-lived increases in blood pressure and heart rate are also common.
PT-141 is contraindicated in people with uncontrolled high blood pressure or known cardiovascular disease. Repeated use has been linked to focal hyperpigmentation, including darkening of the face and gums. Anyone considering it should talk with a healthcare professional rather than self-dosing with products bought online.
In the United States, bremelanotide is a prescription drug. It is not approved for men or for postmenopausal women, so use in those groups is off-label. The approved answer to what is pt 141 peptide used for is deliberately narrow: acquired, generalized HSDD in premenopausal women.
Research-Grade PT-141 and What Is Still Unknown
Many online vendors sell a research peptide labeled for laboratory use only and not for human consumption. Those products are not FDA-reviewed, their purity and actual contents can vary, and injecting them carries risks that have nothing to do with the approved drug.
Researchers continue to study melanocortin agonists in men, in postmenopausal women, and in combination with other therapies. Long-term safety data outside the approved population remains limited, and no peptide in this class is approved as a general-use aphrodisiac.
Bottom line: PT-141 is a real, FDA-approved prescription peptide with a central mechanism of action, a narrow approved indication, and meaningful side effects. It is not an over-the-counter supplement, and it is not the same thing as a PDE5 inhibitor.
Frequently Asked Questions
Is PT-141 a peptide?
Yes. PT-141, also called bremelanotide, is a synthetic cyclic heptapeptide made of seven amino acids and modeled on alpha-MSH, a peptide the body produces naturally. It is a melanocortin receptor agonist, not a hormone and not a vasodilator.
Is PT-141 FDA-approved?
Yes, bremelanotide is FDA-approved under the brand name Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is not approved for men or postmenopausal women, and in the United States it is available by prescription only.
How long does PT-141 take to work and how long does it last?
The injectable is typically given at least 45 minutes before sexual activity, and many users report onset within 30 to 60 minutes. Effects are usually described as lasting a few hours, and dosing is limited to one injection per 24 hours and no more than eight injections per month.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.